MA29714B1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA29714B1
MA29714B1 MA30239A MA30239A MA29714B1 MA 29714 B1 MA29714 B1 MA 29714B1 MA 30239 A MA30239 A MA 30239A MA 30239 A MA30239 A MA 30239A MA 29714 B1 MA29714 B1 MA 29714B1
Authority
MA
Morocco
Prior art keywords
vzv
adjuvant
vaccine
shingles
mpl
Prior art date
Application number
MA30239A
Other languages
English (en)
French (fr)
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29714(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29714B1 publication Critical patent/MA29714B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA30239A 2005-03-03 2007-09-24 Vaccin MA29714B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine

Publications (1)

Publication Number Publication Date
MA29714B1 true MA29714B1 (fr) 2008-09-01

Family

ID=34430592

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30239A MA29714B1 (fr) 2005-03-03 2007-09-24 Vaccin

Country Status (35)

Country Link
US (3) US20080171079A1 (Direct)
EP (4) EP2301955B1 (Direct)
JP (2) JP5420842B2 (Direct)
KR (2) KR20140006115A (Direct)
CN (2) CN101189254B (Direct)
AR (2) AR052498A1 (Direct)
AU (1) AU2006222225B2 (Direct)
BE (1) BE2018C035I2 (Direct)
BR (1) BRPI0607840B1 (Direct)
CA (2) CA2882255C (Direct)
CY (5) CY1116108T1 (Direct)
DK (4) DK2301955T3 (Direct)
EA (1) EA011884B1 (Direct)
ES (4) ES2618037T3 (Direct)
GB (1) GB0504436D0 (Direct)
HR (4) HRP20150142T1 (Direct)
HU (4) HUE038467T2 (Direct)
IL (1) IL185442A (Direct)
LT (4) LT2281831T (Direct)
LU (1) LUC00087I2 (Direct)
MA (1) MA29714B1 (Direct)
MX (2) MX346865B (Direct)
MY (1) MY148464A (Direct)
NL (1) NL300951I2 (Direct)
NO (2) NO341841B1 (Direct)
NZ (1) NZ561075A (Direct)
PE (2) PE20061287A1 (Direct)
PL (4) PL2281830T3 (Direct)
PT (4) PT1858917E (Direct)
SI (4) SI1858917T1 (Direct)
TR (2) TR201809393T4 (Direct)
TW (1) TWI403517B (Direct)
UA (1) UA94900C2 (Direct)
WO (1) WO2006094756A2 (Direct)
ZA (1) ZA200707144B (Direct)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
KR20100063030A (ko) * 2007-07-19 2010-06-10 노바백스, 인코포레이티드 바리셀라 조스터 바이러스-바이러스 유사 입자(ＶＬＰｓ) 및 항원
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
SI2590626T1 (sl) 2010-07-06 2016-01-29 Glaxosmithkline Biologicals S.A. Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
HUE061068T2 (hu) 2010-08-31 2023-05-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNS szállítására
US20140030292A1 (en) 2010-10-11 2014-01-30 Novartis Ag Antigen delivery platforms
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2015050181A1 (ja) * 2013-10-03 2015-04-09 日東電工株式会社 注射ワクチン組成物
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
CA2970840A1 (en) * 2014-12-18 2016-06-23 Glaxosmithkline Biologicals S.A. Vaccine composition comprising truncated varicella zoster virus glycoprotein e antigen
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
US11643441B1 (en) * 2015-10-22 2023-05-09 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (VZV)
CN112812143A (zh) 2015-11-06 2021-05-18 佐剂技术公司 三萜皂苷类似物
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
KR102028463B1 (ko) * 2016-11-25 2019-10-04 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
AU2017389221B2 (en) * 2016-12-26 2020-10-08 Access To Advanced Health Institute Herpes zoster vaccine composition
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
EP3615039A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
CA3061205A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
CN110621339A (zh) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
US12016919B2 (en) 2017-05-30 2024-06-25 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
EP3697802A4 (en) 2017-10-16 2021-11-24 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
WO2019225962A1 (ko) * 2018-05-23 2019-11-28 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스의 항원 변이체 및 이의 용도
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN113164586B (zh) * 2018-09-27 2024-04-16 武汉博沃生物科技有限公司 免疫组合物及其制备方法与应用
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
CN115177724A (zh) * 2019-06-28 2022-10-14 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
US20230040021A1 (en) * 2019-12-13 2023-02-09 Grand Theravac Life Science (Nanjing) Co., Ltd. Immunostimulatory composition and use thereof
WO2021172971A1 (ko) * 2020-02-28 2021-09-02 (주)셀트리온 수두 대상포진 바이러스 융합 단백질 및 이를 포함하는 면역원성 조성물
CA3188708A1 (en) 2020-08-07 2022-02-10 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
EP4212173A4 (en) 2020-09-11 2024-10-23 Eubiologics Co., Ltd. Vaccine composition for chickenpox or varicella zoster and method of using same
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
EP4416274A2 (en) 2021-10-15 2024-08-21 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
JP2024541466A (ja) 2021-11-24 2024-11-08 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 水痘帯状疱疹ウイルス免疫原組成物及びその使用
CN116327912A (zh) * 2021-12-23 2023-06-27 上海泽润生物科技有限公司 带状疱疹疫苗组合物
CN116350770B (zh) * 2021-12-28 2024-07-12 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production
CN116655748B (zh) * 2023-02-28 2024-07-26 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
CN118240844B (zh) * 2024-05-27 2024-12-13 北京悦康科创医药科技股份有限公司 带状疱疹mRNA疫苗及其制备方法和应用
WO2026006687A1 (en) * 2024-06-28 2026-01-02 Orbital Therapeutics, Inc. Circular rna compositions and uses thereof for diseases caused by varicella-zoster virus
CN120081913B (zh) * 2025-05-08 2025-08-12 江苏华诺泰生物医药科技有限公司 一种重组带状疱疹病毒原液的纯化方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (Direct) * 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2071770T3 (es) 1989-06-27 1995-07-01 Smithkline Beecham Biolog Nuevos compuestos.
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
DK0651789T4 (da) * 1992-07-17 2009-07-27 Merck & Co Inc Fremgangsmåde til at forebygge zoster eller lindre varicella-forbundet post-herpetisk neuralgia
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CA2215394C (en) * 1995-03-23 2011-04-26 Immunex Corporation Il-17 receptor
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
PL190237B1 (pl) 1997-04-01 2005-11-30 Corixa Corp Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
ES2295229T3 (es) * 2000-10-18 2008-04-16 Glaxosmithkline Biologicals S.A. Vacunas contra canceres.
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
DK1858917T3 (da) 2015-02-02
AU2006222225A1 (en) 2006-09-14
LTC2281831I2 (lt) 2020-08-25
EP2281831A2 (en) 2011-02-09
HUE032544T2 (en) 2017-10-30
ES2618037T3 (es) 2017-06-20
EA011884B1 (ru) 2009-06-30
NO341841B1 (no) 2018-02-05
KR101357204B1 (ko) 2014-02-06
TWI403517B (zh) 2013-08-01
LUC00087I2 (Direct) 2018-11-26
ES2675054T3 (es) 2018-07-06
MX346865B (es) 2017-04-04
DK2301955T3 (en) 2018-06-14
CN101189254A (zh) 2008-05-28
CN103028113A (zh) 2013-04-10
WO2006094756A3 (en) 2007-02-15
CY2018025I1 (el) 2018-12-12
PL1858917T3 (pl) 2015-05-29
BRPI0607840B1 (pt) 2021-06-29
NO20074392L (no) 2007-11-27
US20080171079A1 (en) 2008-07-17
US20110104260A1 (en) 2011-05-05
CY1120347T1 (el) 2018-12-12
HUE038467T2 (hu) 2018-10-29
CY1118629T1 (el) 2017-07-12
PL2281831T3 (pl) 2018-08-31
CN103028113B (zh) 2015-05-20
DK2281831T3 (en) 2018-06-14
CA2600905A1 (en) 2006-09-14
HK1111427A1 (en) 2008-08-08
ES2532803T3 (es) 2015-03-31
ZA200707144B (en) 2009-11-25
AR107285A2 (es) 2018-04-18
HUS1800038I1 (hu) 2018-10-29
AU2006222225B2 (en) 2012-08-16
CN101189254B (zh) 2013-05-22
EP2281830B1 (en) 2016-12-21
HRP20180988T1 (hr) 2018-08-10
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
CY1116108T1 (el) 2017-02-08
TR201809393T4 (tr) 2018-07-23
WO2006094756A2 (en) 2006-09-14
PL2301955T3 (pl) 2018-08-31
LTPA2018012I1 (lt) 2018-11-12
HRP20170081T1 (hr) 2017-03-24
PT1858917E (pt) 2015-02-24
US7939084B1 (en) 2011-05-10
KR20140006115A (ko) 2014-01-15
BRPI0607840A2 (pt) 2009-06-13
NO2018033I1 (no) 2018-09-20
EP2301955B1 (en) 2018-04-18
EP2281831B1 (en) 2018-04-18
NZ561075A (en) 2009-06-26
CA2882255C (en) 2018-03-27
MX2007010626A (es) 2007-10-16
SI2301955T1 (en) 2018-07-31
HUE038468T2 (hu) 2018-10-29
ES2675055T3 (es) 2018-07-06
EP2301955A3 (en) 2011-11-16
SI2281831T1 (en) 2018-07-31
TW200643028A (en) 2006-12-16
LT2281830T (lt) 2017-02-10
NL300951I2 (nl) 2020-08-31
JP2013144710A (ja) 2013-07-25
US20110045059A1 (en) 2011-02-24
SI1858917T1 (sl) 2015-03-31
EP1858917B1 (en) 2014-12-24
EP2301955A2 (en) 2011-03-30
EP1858917A2 (en) 2007-11-28
EP1858917B8 (en) 2015-05-06
PE20061287A1 (es) 2006-12-07
PL2281830T3 (pl) 2017-06-30
PE20100658A1 (es) 2010-10-23
EP2281831A3 (en) 2011-11-16
CY1121211T1 (el) 2020-05-29
LT2301955T (lt) 2018-07-10
HRP20180989T1 (hr) 2018-08-10
EP2281830A3 (en) 2012-01-25
LT2281831T (lt) 2018-07-10
PT2281830T (pt) 2017-02-24
HRP20150142T1 (hr) 2015-05-22
DK2281830T3 (en) 2017-03-20
IL185442A0 (en) 2008-01-06
EP2281830A2 (en) 2011-02-09
NL300951I1 (nl) 2018-09-26
JP5840167B2 (ja) 2016-01-06
BE2018C035I2 (Direct) 2025-09-05
JP2008531637A (ja) 2008-08-14
PT2281831T (pt) 2018-06-15
CY2018025I2 (el) 2018-12-12
SI2281830T1 (sl) 2017-03-31
GB0504436D0 (en) 2005-04-06
CA2600905C (en) 2015-05-05
MY148464A (en) 2013-04-30
CA2882255A1 (en) 2006-09-14
EA200701632A1 (ru) 2008-02-28
PT2301955T (pt) 2018-06-18
JP5420842B2 (ja) 2014-02-19
AR052498A1 (es) 2007-03-21
KR20070110413A (ko) 2007-11-16
IL185442A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
MA29714B1 (fr) Vaccin
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
CR10101A (es) Nueva composición
EP3058954A3 (en) Immunogenic compositions and methods
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
CU23552A1 (es) Composición vacunal
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BRPI0508813A (pt) vacinas de combinação com baixa dose de conjugado de hib
WO2006062807A3 (en) Compositions with enhanced immunogenicity
MX2010004626A (es) Vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas.
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
WO2007123906A3 (en) Recombinant antigens for diagnosis and prevention of murine typhus
MA32003B1 (fr) Vaccin
EA200702079A1 (ru) Вакцина
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
MA32080B1 (fr) Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1
ITRM20050064A1 (it) Peptide poliepitopico derivato dalla timidilato sintetasi avente attivita' immunologica e antitumorale e composizioni farmaceutiche relative.
SE0102184D0 (sv) New subject-matter
WO2009129498A3 (en) Substance p and analogs thereof as a cancer immunogenic composition adjuvant
ATE431745T1 (de) Ltb4 als adjuvans für impfstoffe
BRPI0318114B8 (pt) Vacinação ou imunização utilizando um regime de iniciação-reforço
TH81397B (th) วัคซีน
DK1204420T3 (da) Trehaloseproducerende prokaryotiske celler som vacciner
WO2008100142A3 (en) Vaccine formulation